Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CUV | Sydney | AUD | Delayed | |
CLVLY | OTC Markets | USD | Delayed | |
CLVLF | OTC Markets | USD | Delayed | |
CUV | TradeGate | EUR | Delayed |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Brenda Mary Shanahan | - | 2007 | Non-Executive Director |
Philippe Jacques Wolgen | 60 | 2005 | CEO, MD & Director |
Jeffrey V. Rosenfeld | - | 2019 | Non-Executive Chairman |
Susan E. Smith | - | 2019 | Non-Executive Director |
Karen A. Agersborg | - | 2018 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review